Atlanta (ots-PRNewswire) - CryoLife, Inc. (NYSE: CRY), the leader
in the development and commercialization of living human tissue
implantable devices and a manufacturer of stentless heart valves and
surgical adhesives, announced that its Board of Directors has
authorized a 3-for-2 stock split, to be effected as a stock
dividend, to shareholders of record on December 8, 2000. New share
certificates will be mailed to shareholders on December 27, 2000.
Fractional shares will be aggregated and sold, with the proceeds
distributed to shareholders in lieu of the issuance of such shares.
CryoLife, Inc. had approximately 12,500,000 common shares outstanding
as of November 27, 2000.
Steven G. Anderson, President and Chief Executive Officer,
CryoLife, Inc. noted, "The action of the Board of Directors follows
the recent increase in the Company's share price and provides an
opportunity to increase the liquidity of the Company. The
availability of additional shares should also enable future
investors to trade more actively in the company's stock".
Founded in 1984, CryoLife, Inc. is the leader in the development
and commercialization of implantable living human tissues for use in
cardiovascular, vascular and orthopaedic surgeries throughout the
United States and Canada. The Company's BioGlue(R) Surgical Adhesive
is approved as an adjunct in the repair of acute thoracic aortic
dissections under HDE regulations in the United States and is CE
marked in the European Union and approved in Canada for use in
vascular and pulmonary sealing and repair. The Company also
manufactures the SynerGraft(R) heart valve, the world's first
tissue-engineered heart valve replacement and the CryoLife-O'Brien(R)
and CryoLife-Ross(R) stentless porcine heart valves, which are CE
marked for distribution within the European Community.
For additional information about the company, visit CryoLife's web
site: http://www.cryolife.com .
ots Original Text Service: CryoLife, Inc.
Contact: Roy Vogeltanz, Vice President, Corporate Communications, of
CryoLife, Inc., 800-438-8285
Web site: http://www.cryolife.com Original-Content von: CryoLife, Inc., übermittelt durch news aktuell